Amitiza (lubiprostone) will come in a new lower strength for treating irritable bowel syndrome with constipation (IBS-C)

June 2008

Amitiza (lubiprostone) will come in a new lower strength for treating irritable bowel syndrome with constipation (IBS-C).

It's the only drug approved for this condition now that Zelnorm (tegaserod) is restricted to emergency use only.

So far, this new indication is just for women...not men.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

More patients AND PARTNERS will get Suprax for gonorrhea
ADHD American Heart Assoc statement is raising a furor because it implies that ALL children on ADHD drugs need an ECG
Migraine Treximet, a new sumatriptan and naproxen combination tablet for migraines
Gastroenterology Amitiza (lubiprostone) will come in a new lower strength for treating irritable bowel syndrome with constipation (IBS-C)
Gastroenterology Cimzia (CIM-zee-uh) is a new biologic therapy for Crohn's disease
Gastroenterology Relistor (REL-i-store) will offer a new option for treating opioid-induced constipation
Hypertension how to treat resistant hypertension
Respiratory & Allergy Patanase (olopatadine) and Omnaris (ciclesonide) nasal sprays for allergic rhinitis
Geriatrics Vitamin D is being used more in the elderly to PREVENT falls
Pediatrics treating metabolic syndrome in kids
Bisphosphonates whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation
Supplements glucosamine alone or with chondroitin can interact with warfarin
Cardiology Is it better to use an ACE inhibitor, angiotensin receptor blocker (ARB), or both in patients at risk for heart disease?